Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 7/20 | 0.40 |
| ▸ | RAF1 | P04049 | 6/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | SLC5A1 | P13866 | 5/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | PPIA | P62937 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776479 | 0.85 | SLC5A1 (0.41) | MEN1KMT2ABRAFRAF1SLC5A1 | |
| SCHEMBL16775900 | 0.85 | LMNA (0.40) | BRAFRAF1SLC5A1CA2CA9 | |
| SCHEMBL16776472 | 0.85 | CA2 (0.41) | BRAFRAF1SLC5A1CA2CA9 | |
| SCHEMBL16776355 | 0.84 | CA2 (0.41) | RXFP1SLC5A1CA2CA9FYN | |
| SCHEMBL19670353 | 0.84 | MEN1 (0.44) | MEN1KMT2ARXFP1BRAFRAF1 | |
| SCHEMBL16776434 | 0.83 | PTGER3 (0.39) | MEN1KMT2ABRAFRAF1SLC5A1 | |
| SCHEMBL16785534 | 0.82 | SLC5A1 (0.43) | BRAFRAF1SLC5A1CA2CA9 | |
| SCHEMBL16776368 | 0.82 | RHOA (0.36) | BRAFRAF1SLC5A1CA2CA9 | |
| SCHEMBL16776293 | 0.82 | CA2 (0.38) | KMT2ABRAFRAF1SLC5A1CA2 | |
| SCHEMBL16775894 | 0.82 | FYN (0.37) | BRAFRAF1CA2CA9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | MEN1 3676/4885KMT2A 1438/4885RXFP1 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.